July 31 (Reuters) - Teva Pharmaceutical Industries

raised its full-year profit forecast on Wednesday,

banking on strength in its generic drug business and strong

sales of its Huntington's disease drug.

Teva now expects its profit for the full year 2024 to be

between $2.30 and $2.50 per share, compared with its previous

expectation of $2.20-$2.50 per share.